Navigation Links
Gamma-Hydroxybutyric Acid, Serum or Plasma

ProductsGamma-Hydroxybutyric Acid, Serum or Plasma
Company ARUP Laboratories
Item Gamma-Hydroxybutyric Acid, Serum or Plasma
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Gamma-Hydroxybutyric Acid, Urine
2. Acid, Urine
3. Aminocaproic Acid, Serum or Plasma
4. Aminocaproic Acid, Urine
5. Carbolic Acid, Urine
6. Citric Acid, Serum
7. Citric Acid, Urine
8. Delta-Aminolevulinic Acid, Urine
9. 2,4-Dichlorophenoxyacetic Acid, Serum or Plasma
10. 2,4-Dichlorophenoxyacetic Acid, Urine
11. Fatty Acid, Stool
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels.
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs.
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis.
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing.
Medicine Products:
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begins -,...- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a le...today that its subsidiary has commenced commercial...es USP product in the 40mg,strength from its Davie...ith the launch, Watson has 180 days of marketing e...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
(Date:7/25/2008)...D, Calif., July 25 /PRNewswire/ -- AutoGenomics, I...on statement on Form S-1 with the,Securities and E...l public,offering of shares of its common stock. T... all of which are expected to be offered by,AutoGe..., have not yet been,determined., J.P. Morgan Secu...
(Date:7/25/2008)... New program delivers immediate cost...4-hour telephone access to language interpreters] ...multilingual solutions. , ...E® http://www.lle-inc.com/index.html [(Langu...er of interpretation, translation, and language in...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3
...tool to treat drug-resistant HIV thanks to a new m...// "There are many treatments for AIDS on the mark...said Arun Ghosh (pronounced A-rune GO-sh), a profe...partments of chemistry and medicinal chemistry and...
...ffer from stress urinary incontinence (SUI), a con...an lead to urine leakage.// “We try to treat pati... better bladder habits, doing Kegel exercises, and...coughing, infections and hormone deficiencies—all ...
...ndometrial cancer should be screened for inherited...al other cancers.// The study showed that 1.8 per...etrial cancer patients have mutations for Lynch sy...wn as hereditary nonpolyposis colon cancer, or HNP...
...-borne viruses is well known; a bite on the body t...od stream. But what happens next that causes the v...searchers led by a Howard Hughes Medical Institute...been able to point at a genetic element which help...
Other Medicine News:Health News:Research Leads to First Treatment for Drug-Resistant HIV 2Health News:Research Leads to First Treatment for Drug-Resistant HIV 3Health News:Research Leads to First Treatment for Drug-Resistant HIV 4Health News:Uterine Cancer May be Clue to Inherited Syndrome 2Health News:Uterine Cancer May be Clue to Inherited Syndrome 3Health News:The Dengue Virus Unplugged 2Health News:The Dengue Virus Unplugged 3
(Date:7/22/2008)...wo Regimens Including Lantus(R) and Apidra(R) Resu... with Type 2 Diabetes, Whatever the Algorithm ....J., July 22 /- Results from the "Adj...Simple Algorithm to Carbohydrate,Counting for Adju...published in the American Diabetes Association,s (...
(Date:7/22/2008)...SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ ...t it has completed patient enrollment,in its Phase...bility and,ammonia scavenging effects of HPN-100 (...henylbutyrate) in patients with urea cycle disorde...esults in the fourth quarter,of this year., (Logo...
(Date:7/22/2008)... Developed and Validated by Columbia University Me...Proprietary MicroRNA Technology, The Test Differ... Lung Cancer (NSCLC), Classifying Squamous-Cell C... Percent and Specificity of 90 Percent,This is the...s, Sensitivity as Biomarkers for Accurate...
(Date:7/22/2008)...SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-Firs...nnounced it has successfully completed the,enrollm...olled hypertension,in two clinical pharmacology st...y announced timelines. These trials are designed t..., in comparison to ibuprofen and,naproxen, using t...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 1Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 2Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 3Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 4Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 5Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 6Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 7Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 8The Quigley Corporation Announces Sale of Its Health and Wellness Segment 13232 1The Quigley Corporation Announces Sale of Its Health and Wellness Segment 13232 2The Quigley Corporation Announces Sale of Its Health and Wellness Segment 13232 3Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 1Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 2Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 1NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 2NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 5
...K, April 10, 2007 /PRNewswire-FirstCall/ -- ImClon...mpany today,announced that a Phase III study of ER...apy) in patients with locally advanced,unresectabl...,primary endpoint of improving overall survival. ,... a cancer,center network sponsored by the National...
...TO, Calif., April 09, 2007 /PRNewswire-FirstCall/ ...a from its,multicenter Phase 2 trial of the triple...286), carboplatin and paclitaxel will be,presented...ation,for Cancer Research (AACR) in Los Angeles. P...lates of synergistic cancer cell growth,inhibition...
Other Medicine Technology:Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3